CDK6 and breast cancer: After a prolonged exposure to CDK4/6 inhibitor LY2835219, a significant amplification of CDK6 was found in several breast cancer cell lines, and this may account for a decreased CDK4/6 targeted phosphorylation of Rb1 and a decreased sensitivity of breast cancer cells to CDK4/6 inhibitor (32).